 |
市場調查報告書
商品編碼
1890921
噬菌體療法市場按產品、目標病原體、疾病適應症、給藥途徑、最終用戶和地區分類Phage Therapy Market, By Product, By Target Pathogen, By Disease Indication, By Route of Administration, By End User, By Geography |
||||||
預計到 2025 年，噬菌體療法市值將達到 13.4 億美元，到 2032 年將達到 20.3 億美元，2025 年至 2032 年的複合年成長率為 6.1%。
| 報告內容 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2024 | 2025年市場規模： | 13.4億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2025年至2032年 |
| 預測期（2025-2032年）複合年成長率： | 6.10% | 2032 年的預測值： | 20.3億美元 |
全球噬菌體療法市場代表了一種利用噬菌體（一種天然存在的病毒，能夠特異性靶向並摧毀致病菌）來治療細菌感染疾病的創新方法。隨著抗生素抗藥性在全球範圍內持續蔓延，噬菌體療法正成為一種極具前景的治療方法選擇，它能夠提供精準醫療手段，以應對對傳統抗生素抗藥性的多重抗藥性細菌感染疾病。這種創新療法利用了噬菌體與細菌之間天然的捕食者-獵物關係，駕馭這些微小的生物體選擇性地清除有害菌株，同時保護有益菌群。
該市場涵蓋多種基於噬菌體的產品，包括個人化噬菌體混合物、標準化治療製劑以及用於細菌鑑定和藥敏試驗的診斷工具。噬菌體療法的應用遍及多個醫學領域，包括治療慢性傷口感染疾病、呼吸道感染疾病、尿道感染和胃腸道疾病。監管機構對噬菌體療法潛力的日益認可，以及研發投入的不斷增加，預計將推動該市場顯著成長。醫療機構和製藥公司正積極探索噬菌體療法作為應對全球抗菌素抗藥性危機的有效解決方案，推動生產流程、品管標準和臨床試驗調查方法的創新，以建立穩健的治療通訊協定。
市場動態
全球噬菌體療法市場正經歷著強勁的成長勢頭，這主要得益於多種因素的推動。其中最突出的因素是日益嚴峻的全球抗生素抗藥性危機，這場危機使得傳統治療方法對多重抗藥性細菌感染疾病束手無策。世界衛生組織（WHO）已將抗菌素抗藥性列為全球十大公共衛生威脅之一，這加速了對替代治療方法的研究投資和監管支持，並將噬菌體療法定位為關鍵解決方案。醫院感染、慢性傷口和細菌生物膜相關疾病的增加進一步推動了市場需求，因為醫療機構正在尋求副作用較少的標靶治療。醫療專業人員和患者對個人化醫療方法的認知不斷提高，加上成功的臨床案例研究證明了噬菌體療法的有效性，這些因素持續推動市場應用。然而，該市場也面臨許多限制因素，例如複雜的法規結構缺乏噬菌體療法的標準化核准途徑，導致研發週期長、成本高昂。
噬菌體穩定性、品管和大規模生產流程等方面的製造挑戰，為商業化帶來了額外的障礙。有限的臨床試驗數據以及需要對多種細菌菌株進行廣泛的安全性和有效性研究，限制了市場的快速擴張。此外，高昂的研發成本、複雜的智慧財產權問題以及對專業儲存和分銷基礎設施的需求，也構成了中小企業進入該市場的障礙。然而，製藥公司和生物技術公司之間的策略聯盟、政府資助的抗菌素抗藥性研究計畫以及在獸醫學和農業領域不斷擴展的應用，都蘊藏著巨大的機會。噬菌體庫的出現、合成生物學技術的進步使得工程化噬菌體成為可能，以及噬菌體與傳統抗生素聯合治療的日益普及，都為市場參與企業提供了盈利的成長路徑。
本次調查的主要特點
- 本報告對全球噬菌體療法市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）內的市場規模（十億美元）和復合年成長率（%）。
- 該報告還重點介紹了各個細分市場的潛在商機，並概述了該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數介紹了全球噬菌體療法市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告的研究結果將使負責人和經營團隊能夠就即將推出的產品、類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球噬菌體療法市場報告的目標受群眾外包括該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 相關人員可以透過各種用於分析全球噬菌體療法市場的策略矩陣輕鬆做出決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
第3章 市場動態、監理及趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 重大進展
- 法規環境
- 產品上市及核准
- PEST分析
- 波特分析
- 併購趨勢
- 產業趨勢
4. 2020-2032年全球噬菌體療法市場（依產品分類）
- 單核細胞療法
- 噬菌體雞尾酒
- 基因工程噬菌體
- 噬菌體衍生酶（例如，內溶素）
- 組合產品（噬菌體+抗生素或佐劑）
5. 2020-2032年全球噬菌體療法市場（以標靶病原體分類）
- 革蘭氏陰性菌
- 革蘭氏陽性菌
6. 2020-2032年全球噬菌體療法市場（依疾病適應症分類）
- 尿道感染（UTI）
- 皮膚和傷口感染疾病
- 骨骼和關節/植入相關感染疾病
- 呼吸道感染疾病（包括囊腫纖維化）
- 胃腸道感染疾病
- 血液感染疾病/敗血症
- 生物膜相關慢性感染疾病
- 其他疾病適應症
7. 2020-2032年全球噬菌體療法市場（依給藥途徑分類）
- 口服
- 局部/皮膚給藥
- 注射劑/靜脈注射（IV/IM）
- 吸入/霧化器
- 局部注射（例如，膀胱內、傷口腔內）
- 其他給藥途徑
8. 2020-2032年全球噬菌體療法市場（依最終用戶分類）
- 醫院和專科診所
- 研究機構和學術中心
- 門診護理/門診診所
- 其他（獸醫診所）
9. 2020-2032年全球噬菌體療法市場（按地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第10章 競爭格局
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGOTAC Therapeutics（or Fagoterapia）
- Evolution Biotechnologies Inc
- Tol ka AI Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
第11章 分析師建議
- 機會
- 分析師觀點
- Coherent Opportunity Map
第12章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Phage Therapy Market is estimated to be valued at USD 1.34 Bn in 2025 and is expected to reach USD 2.03 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.1% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 6.10% | 2032 Value Projection: | USD 2.03 Bn |
The global phage therapy market represents a revolutionary approach to combating bacterial infections through the therapeutic application of bacteriophages, naturally occurring viruses that specifically target and destroy bacterial pathogens. As antibiotic resistance continues to escalate worldwide, phage therapy has emerged as a promising alternative treatment modality, offering precision medicine capabilities that can address multidrug-resistant bacterial infections where conventional antibiotics have failed. This innovative therapeutic approach leverages the natural predator-prey relationship between bacteriophages and bacteria, utilizing these microscopic entities to selectively eliminate harmful bacterial strains while preserving beneficial microbiota.
The market encompasses various phage-based products, including personalized phage cocktails, standardized therapeutic formulations, and diagnostic tools for bacterial identification and susceptibility testing. Phage therapy applications span across multiple medical domains, including treatment of chronic wound infections, respiratory tract infections, urinary tract infections, and gastrointestinal disorders. The growing recognition of phage therapy's potential by regulatory bodies, coupled with increasing investment in research and development activities, has positioned this market for substantial growth. Healthcare providers and pharmaceutical companies are increasingly exploring phage therapy as a viable solution to address the global antimicrobial resistance crisis, driving innovation in manufacturing processes, quality control standards, and clinical trial methodologies to establish robust therapeutic protocols.
Market Dynamics
The global phage therapy market is experiencing significant growth momentum driven by multiple compelling factors, with the most prominent being the escalating global crisis of antibiotic resistance that has rendered many conventional treatments ineffective against multidrug-resistant bacterial infections. The World Health Organization's classification of antimicrobial resistance as one of the top ten global public health threats has accelerated research investments and regulatory support for alternative therapeutic approaches, positioning phage therapy as a critical solution. Increasing prevalence of hospital-acquired infections, chronic wounds, and bacterial biofilm-associated diseases further amplifies market demand, as healthcare providers seek targeted treatments with minimal side effects. Growing awareness among healthcare professionals and patients about personalized medicine approaches, combined with successful clinical case studies demonstrating phage therapy efficacy, continues to drive market adoption. However, the market faces significant restraints including complex regulatory frameworks that lack standardized approval pathways for phage-based therapeutics, creating lengthy and expensive development timelines.
Manufacturing challenges related to phage stability, quality control, and large-scale production processes pose additional barriers to commercialization. Limited clinical trial data and the need for extensive safety and efficacy studies across diverse bacterial strains constrain rapid market expansion. Furthermore, high development costs, intellectual property complexities, and the requirement for specialized storage and distribution infrastructure create entry barriers for smaller companies. Nevertheless, substantial opportunities exist through strategic partnerships between pharmaceutical companies and biotechnology firms, government funding initiatives supporting antimicrobial resistance research, and expanding applications in veterinary medicine and agriculture. The emergence of phage banks, advances in synthetic biology enabling engineered phages, and growing acceptance of combination therapies integrating phages with traditional antibiotics present lucrative growth avenues for market participants.
Key Features of the Study
- This report provides in-depth analysis of the global phage therapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global phage therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Armata Pharmaceuticals Inc, BiomX Inc, Pherecydes Pharma SAS, Intralytix Inc, Locus Biosciences Inc, Nextbiotics Ltd, Proteon Pharmaceuticals SA, iNtRON Biotechnology Co Ltd, Micreos BV, Eligo Bioscience SA, FAGOTAC Therapeutics (or Fagoterapia), Evolution Biotechnologies Inc, Tol ka AI Therapeutics Inc, PrecisionPhage Oy, and Obulytix Inc
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global phage therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global phage therapy market
Market Segmentation
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Monophage therapy
- Phage cocktails
- Engineered/recombinant phages
- Phage derived enzymes (e.g., endolysins)
- Combination products (phage + antibiotic or adjunct)
- Target Pathogen Insights (Revenue, USD Bn, 2020 - 2032)
- Gram negative bacteria
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram-negative bacteria
- Gram positive bacteria
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram-positive bacteria
- Mixed/other pathogens
- Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Urinary tract infections (UTIs)
- Skin and wound infections
- Bone and joint/implant associated infections
- Respiratory tract infections (including cystic fibrosis)
- Gastrointestinal infections
- Bloodstream/sepsis infections
- Biofilm related chronic infections
- Other indications
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Topical/dermal
- Injectable/intravenous (IV/IM)
- Inhalation/nebulized
- Local instillation (e.g., bladder, wound cavity)
- Other routes
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals and specialty clinics
- Research institutes and academic centers
- Ambulatory care/outpatient clinics
- Others (Veterinary clinics)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Armata Pharmaceuticals Inc
- BiomX Inc
- Pherecydes Pharma SAS
- Intralytix Inc
- Locus Biosciences Inc
- Nextbiotics Ltd
- Proteon Pharmaceuticals SA
- iNtRON Biotechnology Co Ltd
- Micreos BV
- Eligo Bioscience SA
- FAGOTAC Therapeutics (or Fagoterapia)
- Evolution Biotechnologies Inc
- Tol ka AI Therapeutics Inc
- PrecisionPhage Oy
- Obulytix Inc
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Phage Therapy Market, By Product
- Global Phage Therapy Market, By Target Pathogen
- Global Phage Therapy Market, By Disease Indication
- Global Phage Therapy Market, By Route of Administration
- Global Phage Therapy Market, By End User
- Global Phage Therapy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Phage Therapy Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Monophage therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage cocktails
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Engineered/recombinant phages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Phage derived enzymes (e.g., endolysins)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Combination products (phage + antibiotic or adjunct)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Phage Therapy Market, By Target Pathogen, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Gram negative bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Escherichia coli
- Pseudomonas aeruginosa
- Salmonella spp.
- Klebsiella pneumoniae
- Other Gram-negative bacteria
- Gram positive bacteria
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Staphylococcus aureus
- Streptococcus spp.
- Other Gram-positive bacteria
- Mixed/other pathogens
6. Global Phage Therapy Market, By Disease Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Urinary tract infections (UTIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Skin and wound infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bone and joint/implant associated infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Respiratory tract infections (including cystic fibrosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gastrointestinal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bloodstream/sepsis infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biofilm related chronic infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Phage Therapy Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Topical/dermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injectable/intravenous (IV/IM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Inhalation/nebulized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Local instillation (e.g., bladder, wound cavity)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Phage Therapy Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and specialty clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research institutes and academic centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ambulatory care/outpatient clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Veterinary clinics)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Phage Therapy Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Target Pathogen, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Disease Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Armata Pharmaceuticals Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- BiomX Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pherecydes Pharma SAS
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intralytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Locus Biosciences Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nextbiotics Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Proteon Pharmaceuticals SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- iNtRON Biotechnology Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Micreos BV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eligo Bioscience SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- FAGOTAC Therapeutics (or Fagoterapia)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Evolution Biotechnologies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Tol ka AI Therapeutics Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- PrecisionPhage Oy
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Obulytix Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
